Cargando…

Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy

INTRODUCTION: A litany of recent evidence supports the morbidity of intra-natal iron-deficiency anemia and its prodrome, iron deficiency. Oral iron administered during second and third trimesters does not get to the developing fetus if the mother is iron deficient. This is especially concerning as t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerb, Jesse, Strauss, William, Derman, Richard, Short, Vanessa, Mendelson, Ben, Bahrain, Huzefa, Auerbach, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170347/
https://www.ncbi.nlm.nih.gov/pubmed/34104372
http://dx.doi.org/10.1177/20406207211018042
_version_ 1783702223779266560
author Gerb, Jesse
Strauss, William
Derman, Richard
Short, Vanessa
Mendelson, Ben
Bahrain, Huzefa
Auerbach, Michael
author_facet Gerb, Jesse
Strauss, William
Derman, Richard
Short, Vanessa
Mendelson, Ben
Bahrain, Huzefa
Auerbach, Michael
author_sort Gerb, Jesse
collection PubMed
description INTRODUCTION: A litany of recent evidence supports the morbidity of intra-natal iron-deficiency anemia and its prodrome, iron deficiency. Oral iron administered during second and third trimesters does not get to the developing fetus if the mother is iron deficient. This is especially concerning as the rapidly developing fetal brain is in particular need of iron sufficiency. Intra-natal iron deficiency is associated with autism, schizophrenia and abnormal brain structure. The obstetrical literature reports an unacceptably high incidence of gastrointestinal adverse events with oral iron. The time iron honored standard in the United States for intravenous iron replenishment in gravidas is iron sucrose. While safe and effective, four to seven visits are required to accomplish what newer formulations can achieve with one. METHODS: Ferumoxytol is a superparamagnetic iron oxide linked to polyglucose sorbitol carboxymethylether-binding elemental iron tightly allowing administration of complete replacement doses in 15–30 min. Herein, we report the results of 131 consecutive, non-selected, iron-deficient second- and third-trimester pregnant women who received either 510 mg of intravenous (IV) ferumoxytol twice or 1020 mg once. RESULTS: Hemoglobin and iron parameter increments were highly statistically significant. No adverse events were reported. We report how a single infusion is safe and effective as the same dose over two visits, saving an unnecessary visit and IV placement, while reducing cost. CONCLUSION: Ferumoxytol represents an efficacious and safe method of administration of IV iron which improves convenience for patients and practitioners, and is cost saving due to fewer visits. PLAIN LANGUAGE SUMMARY: One or two infusions of intravenous iron for iron deficiency or iron-deficiency anemia of pregnancy simplifies care This study was conducted to highlight the inconvenience of multiple doses of IV iron and how administering the same dose in one or two infusions simplifies care. We report how a single infusion is as safe and effective as the same dose over two visits, saving an unnecessary visit and IV placement, while reducing cost. This study supports a growing body of evidence, to date, unreported, with ferumoxytol in pregnancy, reporting improved convenience and decreased costs with higher doses of IV iron in one or two visits.
format Online
Article
Text
id pubmed-8170347
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81703472021-06-07 Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy Gerb, Jesse Strauss, William Derman, Richard Short, Vanessa Mendelson, Ben Bahrain, Huzefa Auerbach, Michael Ther Adv Hematol Original Research INTRODUCTION: A litany of recent evidence supports the morbidity of intra-natal iron-deficiency anemia and its prodrome, iron deficiency. Oral iron administered during second and third trimesters does not get to the developing fetus if the mother is iron deficient. This is especially concerning as the rapidly developing fetal brain is in particular need of iron sufficiency. Intra-natal iron deficiency is associated with autism, schizophrenia and abnormal brain structure. The obstetrical literature reports an unacceptably high incidence of gastrointestinal adverse events with oral iron. The time iron honored standard in the United States for intravenous iron replenishment in gravidas is iron sucrose. While safe and effective, four to seven visits are required to accomplish what newer formulations can achieve with one. METHODS: Ferumoxytol is a superparamagnetic iron oxide linked to polyglucose sorbitol carboxymethylether-binding elemental iron tightly allowing administration of complete replacement doses in 15–30 min. Herein, we report the results of 131 consecutive, non-selected, iron-deficient second- and third-trimester pregnant women who received either 510 mg of intravenous (IV) ferumoxytol twice or 1020 mg once. RESULTS: Hemoglobin and iron parameter increments were highly statistically significant. No adverse events were reported. We report how a single infusion is safe and effective as the same dose over two visits, saving an unnecessary visit and IV placement, while reducing cost. CONCLUSION: Ferumoxytol represents an efficacious and safe method of administration of IV iron which improves convenience for patients and practitioners, and is cost saving due to fewer visits. PLAIN LANGUAGE SUMMARY: One or two infusions of intravenous iron for iron deficiency or iron-deficiency anemia of pregnancy simplifies care This study was conducted to highlight the inconvenience of multiple doses of IV iron and how administering the same dose in one or two infusions simplifies care. We report how a single infusion is as safe and effective as the same dose over two visits, saving an unnecessary visit and IV placement, while reducing cost. This study supports a growing body of evidence, to date, unreported, with ferumoxytol in pregnancy, reporting improved convenience and decreased costs with higher doses of IV iron in one or two visits. SAGE Publications 2021-05-31 /pmc/articles/PMC8170347/ /pubmed/34104372 http://dx.doi.org/10.1177/20406207211018042 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Gerb, Jesse
Strauss, William
Derman, Richard
Short, Vanessa
Mendelson, Ben
Bahrain, Huzefa
Auerbach, Michael
Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy
title Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy
title_full Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy
title_fullStr Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy
title_full_unstemmed Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy
title_short Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy
title_sort ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170347/
https://www.ncbi.nlm.nih.gov/pubmed/34104372
http://dx.doi.org/10.1177/20406207211018042
work_keys_str_mv AT gerbjesse ferumoxytolforthetreatmentofirondeficiencyandirondeficiencyanemiaofpregnancy
AT strausswilliam ferumoxytolforthetreatmentofirondeficiencyandirondeficiencyanemiaofpregnancy
AT dermanrichard ferumoxytolforthetreatmentofirondeficiencyandirondeficiencyanemiaofpregnancy
AT shortvanessa ferumoxytolforthetreatmentofirondeficiencyandirondeficiencyanemiaofpregnancy
AT mendelsonben ferumoxytolforthetreatmentofirondeficiencyandirondeficiencyanemiaofpregnancy
AT bahrainhuzefa ferumoxytolforthetreatmentofirondeficiencyandirondeficiencyanemiaofpregnancy
AT auerbachmichael ferumoxytolforthetreatmentofirondeficiencyandirondeficiencyanemiaofpregnancy